Message #28 From:
Stock News Bot Date: February 22, 2007 06:30:00 AM
NPHC News The Wall Street Transcript Interviews Nutra Pharma Chairman and CEO
BOCA RATON, Fla.--(BUSINESS WIRE)--Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing drugs for HIV and Multiple Sclerosis has today announced that its Chairman and CEO, Rik J. Deitsch, has been interviewed for the spring biotechnology issue of The Wall Street Transcript.
“It is an honor to be invited to interview with such a prestigious publication,” commented Mr. Deitsch. “This interview provides Nutra Pharma with a perfect opportunity to outline our current market environment, our recent business developments, and our ongoing goals and strategies,” he added.
In the interview, Mr. Deitsch discusses Nutra Pharma's focus on the research being conducted in diseases that lack therapeutic options, specifically HIV/AIDS, Adrenomyeloneuropathy (AMN), and Multiple Sclerosis (MS). Additionally, he discusses the Company's breakthrough medical diagnostic test kits being developed through its wholly owned subsidiary Designer Diagnostics.
The spring biotechnology issue of The Wall Street Transcript will be published and available to the public in April 2007.
About Nutra Pharma Corp.
Nutra Pharma Corp. is a biopharmaceutical company specializing in the acquisition, licensing and commercialization of pharmaceutical products and technologies for the management of neurological disorders, cancer, autoimmune and infectious diseases. Nutra Pharma Corp. through its subsidiaries carries out basic drug discovery research and clinical development and also seeks strategic licensing partnerships to reduce the risks associated with the drug development process. The Company's holding, ReceptoPharm, Inc, is developing technologies for the production of drugs for HIV and Multiple Sclerosis ("MS"). The Company's subsidiary, Designer Diagnostics is engaged in the research and development of diagnostic test kits designed to be used for the rapid identification of infectious diseases such as Tuberculosis (TB) and Mycobacterium avium-intracellulare (MAI). Nutra Pharma continues to identify and acquire intellectual property and companies in the biotechnology arena.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). The Wall Street Transcript interview should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.
